S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:HLVX

HilleVax (HLVX) Stock Price, News & Analysis

$16.63
+1.01 (+6.47%)
(As of 03/28/2024 ET)
Today's Range
$15.56
$17.23
50-Day Range
$14.15
$19.75
52-Week Range
$9.94
$20.22
Volume
217,270 shs
Average Volume
126,181 shs
Market Capitalization
$826.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.67

HilleVax MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
84.4% Upside
$30.67 Price Target
Short Interest
Healthy
3.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of HilleVax in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$986.29 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.22) to ($3.38) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.76 out of 5 stars

Medical Sector

448th out of 938 stocks

Biological Products, Except Diagnostic Industry

67th out of 153 stocks

HLVX stock logo

About HilleVax Stock (NASDAQ:HLVX)

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

HLVX Stock Price History

HLVX Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
HilleVax (NASDAQ:HLVX) Trading 4.6% Higher
HilleVax's (HLVX) "Buy" Rating Reiterated at HC Wainwright
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Recap: HilleVax Q4 Earnings
Aditya Kohli's Net Worth
HilleVax Appoints GSK's Sean McLoughlin As COO
See More Headlines
Receive HLVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:HLVX
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.67
High Stock Price Target
$34.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+80.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-123,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
35,139,000
Market Cap
$844.40 million
Optionable
Not Optionable
Beta
0.68
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Robert M. Hershberg M.D.Dr. Robert M. Hershberg M.D. (Age 62)
    Ph.D., President, CEO & Chairman of the Board
    Comp: $1.02M
  • Dr. Aditya Kohli Ph.D. (Age 35)
    Chief Business Officer & Director
    Comp: $782.44k
  • Mr. Shane A. Maltbie (Age 42)
    CFO & Treasurer
  • Mr. Sean McLoughlin (Age 52)
    Chief Operating Officer
  • Dr. Anju Chatterji Ph.D.
    Chief Technology Officer
  • Mr. Paul S. Bavier J.D. (Age 52)
    General Counsel, Secretary & Chief Administrative Officer
  • Ms. Astrid Borkowski M.D. (Age 54)
    Ph.D., Chief Medical Officer
  • Mr. Ozzie Berger
    Senior Vice President of Regulatory Affairs

HLVX Stock Analysis - Frequently Asked Questions

Should I buy or sell HilleVax stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HilleVax in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HLVX shares.
View HLVX analyst ratings
or view top-rated stocks.

What is HilleVax's stock price target for 2024?

3 analysts have issued 12 month price objectives for HilleVax's stock. Their HLVX share price targets range from $28.00 to $34.00. On average, they anticipate the company's share price to reach $30.67 in the next year. This suggests a possible upside of 84.4% from the stock's current price.
View analysts price targets for HLVX
or view top-rated stocks among Wall Street analysts.

How have HLVX shares performed in 2024?

HilleVax's stock was trading at $16.05 at the beginning of 2024. Since then, HLVX shares have increased by 3.6% and is now trading at $16.63.
View the best growth stocks for 2024 here
.

Are investors shorting HilleVax?

HilleVax saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 474,900 shares, an increase of 10.2% from the February 29th total of 431,000 shares. Based on an average daily volume of 127,400 shares, the short-interest ratio is presently 3.7 days. Currently, 3.2% of the shares of the company are sold short.
View HilleVax's Short Interest
.

When is HilleVax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our HLVX earnings forecast
.

What ETFs hold HilleVax's stock?

ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM).

When did HilleVax IPO?

HilleVax (HLVX) raised $200 million in an IPO on Friday, April 29th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share.

Who are HilleVax's major shareholders?

HilleVax's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (3.81%), Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.02%), Catalys Pacific LLC (2.70%), Citadel Advisors LLC (1.50%) and Northern Trust Corp (0.51%). Insiders that own company stock include Aditya Kohli, Astrid Borkowski, Robert Hershberg and Shane Maltbie.
View institutional ownership trends
.

How do I buy shares of HilleVax?

Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HLVX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners